$48.47 Million in Sales Expected for Definitive Healthcare Corp. (NASDAQ:DH) This Quarter

Wall Street analysts forecast that Definitive Healthcare Corp. (NASDAQ:DHGet Rating) will report $48.47 million in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Definitive Healthcare’s earnings, with the highest sales estimate coming in at $49.11 million and the lowest estimate coming in at $48.12 million. The firm is expected to report its next quarterly earnings results after the market closes on Monday, January 1st.

According to Zacks, analysts expect that Definitive Healthcare will report full-year sales of $220.07 million for the current year, with estimates ranging from $219.15 million to $220.92 million. For the next financial year, analysts expect that the firm will report sales of $274.82 million, with estimates ranging from $267.55 million to $281.31 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that that provide coverage for Definitive Healthcare.

Definitive Healthcare (NASDAQ:DHGet Rating) last issued its quarterly earnings results on Wednesday, February 23rd. The company reported $0.04 EPS for the quarter, beating analysts’ consensus estimates of $0.02 by $0.02. The business had revenue of $46.31 million for the quarter, compared to the consensus estimate of $44.78 million.

A number of analysts have recently weighed in on the company. Zacks Investment Research lowered Definitive Healthcare from a “hold” rating to a “sell” rating in a research note on Monday, April 18th. Deutsche Bank Aktiengesellschaft increased their price objective on Definitive Healthcare from $21.00 to $26.00 and gave the company a “hold” rating in a research note on Tuesday, April 5th. Canaccord Genuity Group raised Definitive Healthcare from a “hold” rating to a “buy” rating in a research note on Thursday, February 24th. Barclays dropped their price target on Definitive Healthcare from $26.00 to $23.00 in a research note on Thursday, February 24th. Finally, Canaccord Genuity Group raised Definitive Healthcare from a “hold” rating to a “buy” rating and dropped their price target for the stock from $46.00 to $28.00 in a research note on Thursday, February 24th. One analyst has rated the stock with a sell rating, seven have given a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $37.00.

NASDAQ:DH opened at $23.65 on Monday. Definitive Healthcare has a fifty-two week low of $18.15 and a fifty-two week high of $50.30. The company has a debt-to-equity ratio of 0.18, a current ratio of 3.77 and a quick ratio of 3.77. The business has a 50 day moving average price of $23.41 and a 200-day moving average price of $27.30.

In related news, CFO Richard Douglas Booth purchased 2,374 shares of Definitive Healthcare stock in a transaction dated Thursday, March 3rd. The stock was purchased at an average cost of $21.06 per share, for a total transaction of $49,996.44. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Several large investors have recently modified their holdings of DH. Advisor Group Holdings Inc. bought a new stake in Definitive Healthcare in the 3rd quarter worth about $26,000. Fifth Third Bancorp increased its holdings in Definitive Healthcare by 78.5% in the 1st quarter. Fifth Third Bancorp now owns 1,185 shares of the company’s stock worth $29,000 after buying an additional 521 shares in the last quarter. Legal & General Group Plc bought a new stake in Definitive Healthcare in the 4th quarter worth about $29,000. Hardy Reed LLC bought a new stake in Definitive Healthcare in the 1st quarter worth about $76,000. Finally, Steph & Co. bought a new stake in Definitive Healthcare in the 4th quarter worth about $88,000. Hedge funds and other institutional investors own 97.34% of the company’s stock.

About Definitive Healthcare (Get Rating)

Definitive Healthcare Corp., together with its subsidiaries, provides healthcare commercial intelligence in the United States. Its solutions provide information on healthcare providers and their activities to help its customers in the area ranging from product development to go-to-market planning, and sales and marketing execution.

Featured Stories

Get a free copy of the Zacks research report on Definitive Healthcare (DH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Definitive Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Definitive Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.